Layolis Fe: Indications, Dosage, Precautions, Adverse Effects
Россия
  • Россия
  • Украина

Layolis Fe – Product information

Manufacture: Actavis
Country: United States
Condition: Birth Control (Contraception), Contraception (Birth Control)
Class: Contraceptives
Form: Tablets
Ingredients: Norethindrone, Ethinyl Estradiol, Ferrous Fumarate, D&c Yellow No. 10 Aluminum Lake, Fd And C Blue No. 1 Aluminum Lake, Fd And C Yellow No. 6 Aluminum Lake, Lactose Monohydrate, Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Povidone, Sodium Starch Glycolate, Spearmint Flavor, Sucralose, Vitamin E

Warning: cigarette smoking and serious cardiovascular events

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4)].

Indications and usage

Layolis Fe is indicated for use by women to prevent pregnancy.

The efficacy of Layolis Fe in women with a body mass index (BMI) of > 35 kg/m2 has not been evaluated.

Dosage and administration

How to Take Layolis Fe

To achieve maximum contraceptive effectiveness, Layolis Fe must be taken exactly as directed. Chew and swallow one tablet without water at the same time every day. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed pills, see FDA-Approved Patient Labeling. Layolis Fe may be administered without regard to meals [see Clinical Pharmacology (12.3)].

How to Start Layolis Fe

Instruct the patient to begin taking Layolis Fe on Day 1 of her menstrual cycle (that is, the first day of her menstrual bleeding). One light green tablet should be taken daily for 24 consecutive days followed by one brown tablet daily for 4 consecutive days [see FDA-Approved Patient Labeling]. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking Layolis Fe other than on the first day of her menstrual cycle.

For postpartum women who do not breastfeed or after a second trimester abortion, Layolis Fe may be started no earlier than 4 weeks postpartum. Recommend use of a non-hormonal back-up method for the first 7 days. When combined oral contraceptives (COCs) are used during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered. The possibility of ovulation and conception before starting COCs should also be considered.

If the patient is switching from a combination hormonal method such as:

  • Another pill
  • Vaginal ring
  • Patch
  • Instruct her to take the first light green pill on the day she would have started a new cycle of her previous birth control pack (Day 1).
  • If she previously used a vaginal ring or transdermal patch, she should start using Layolis Fe on the day she would have restarted the ring or patch.
  • Instruct the patient to use a non-hormonal back-up method such as a condom and spermicide for the first 7 days.

If the patient is switching from a progestin-only method such as:

  • Progestin-only pill
  • Implant
  • Intrauterine system
  • Injection
    • Instruct her to take the first light green pill on the day she would have taken her next progestin-only pill or on the day of removal of her implant or intrauterine system or on the day when she would have had her next injection.
    • Instruct the patient to use a non-hormonal back-up method such as a condom and spermicide for the first 7 days.

    Advice in Case of Gastrointestinal Disturbances

    In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3-4 hours after taking a light green tablet, this can be regarded as a missed tablet [see FDA-Approved Patient Labeling].

    Dosage forms and strengths

    Layolis Fe is available in blister packs.

    Each blister pack (28 tablets) contains in the following order:

    • 24 light green, round tablets (active) imprinted with “WC” on one side and “483” on the other and each containing 0.8 mg norethindrone and 0.025 mg ethinyl estradiol.
    • 4 brown, round tablets (non-hormonal placebo) imprinted with “WC” on one side and “624” on the other and each containing 75 mg ferrous fumarate. The ferrous fumarate chewable tablets do not serve any therapeutic purpose.

    Contraindications

    Do not prescribe Layolis Fe to women who are known to have the following:

    • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
      • Smoke, if over age 35 [see Boxed Warning, and Warnings and Precautions (5.1)]
      • Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)]
      • Have cerebrovascular disease [see Warnings and Precautions (5.1)]
      • Have coronary artery disease [see Warnings and Precautions (5.1)]
      • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)]
      • Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)]
      • Have uncontrolled hypertension [see Warnings and Precautions (5.4)]
      • Have diabetes with vascular disease [see Warnings and Precautions (5.6)]
      • Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings and Precautions(5.7)]
      • Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past [see Warnings and Precautions (5.2)]
    • Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.3), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)]
    • Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8)]
    • Pregnancy, because there is no reason to use COCs during pregnancy [see Warnings and Precautions (5.9) and Use in Specific Populations (8.1)]

    Warnings and precautions

    Thrombotic and Other Vascular Events

    Stop Layolis Fe if an arterial or deep venous thrombotic (VTE) event occurs. Although the use of COCs increases the risk of venous thromboembolism, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. The risk of venous thromboembolism in women using COCs is 3 to 9 per 10,000 woman-years. The excess risk is highest during the first year of use of a COC. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.

    If feasible, stop Layolis Fe at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism.

    Start Layolis Fe no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

    COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (> 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors.

    Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.

    Stop Layolis Fe if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately

    Carcinoma of the Breasts and Reproductive Organs

    Women who currently have or have had breast cancer should not use Layolis Fe because breast cancer is a hormonally-sensitive tumor.

    There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.

    Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors.

    Liver Disease

    Discontinue Layolis Fe if jaundice develops. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded.

    Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

    Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.

    Oral contraceptive-related cholestasis may occur in women with a history of pregnancy-related cholestasis. Women with a history of COC-related cholestasis may have the condition recur with subsequent COC use.

    High Blood Pressure

    For women with well-controlled hypertension, monitor blood pressure and stop Layolis Fe if blood pressure rises significantly. Women with uncontrolled hypertension or hypertension with vascular disease should not use COCs.

    An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use. The incidence of hypertension increases with increasing concentration of progestin.

    Gallbladder Disease

    Studies suggest the relative risk of developing gallbladder disease may be increased among COC users.

    Carbohydrate and Lipid Metabolic Effects

    Carefully monitor prediabetic and diabetic women who are taking Layolis Fe. COCs may decrease glucose tolerance in a dose-related fashion.

    Consider alternative contraception for women with uncontrolled dyslipidemia. A small proportion of women will have adverse lipid changes while on COCs.

    Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.

    Headache

    If a woman taking Layolis Fe develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Layolis Fe if indicated.

    An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.

    Bleeding Irregularities

    Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC.

    Patient diaries from the clinical trial of Layolis Fe showed that on the first cycle of use, 37% of subjects taking Layolis Fe had unscheduled bleeding and/or spotting. From Cycle 2-13, the percent of women with unscheduled bleeding/spotting ranged from 21-31% per cycle. For those women with unscheduled bleeding/spotting, the mean number of days of unscheduled bleeding/spotting was 5.2 in the first cycle of use and ranged from 3.6 – 4.2 in cycles 2-13. A total of 15 subjects out of 1,677 (0.9%) discontinued the study prematurely due to metrorrhagia or irregular menstruation.

    Women who are not pregnant and use Layolis Fe may not have scheduled (withdrawal) bleeding every cycle or may experience amenorrhea (absence of any bleeding and spotting). The incidence of amenorrhea in the clinical trial increased from 8.1% of the subjects in Cycle 2 to 18.4% by Cycle 13. For those women who had scheduled (withdrawal) bleeding, the average duration of bleeding per cycle in Cycles 2-13 was 3.7 days.

    If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.

    Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.

    COC Use Before or During Early Pregnancy

    Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy. Layolis Fe use should be discontinued if pregnancy is confirmed.

    The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations (8.1)].

    Depression

    Women with a history of depression should be carefully observed and Layolis Fe discontinued if depression recurs to a serious degree.

    Interference with Laboratory Tests

    The use of COCs may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs.

    Monitoring

    A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.

    Other Conditions

    In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking COCs.

    Adverse reaction

    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

    • Serious cardiovascular events and smoking [see Boxed Warning, and Warnings and Precautions (5.1)]
    • Vascular events [see Warnings and Precautions (5.1)]
    • Liver disease [see Warnings and Precautions (5.3)]

    Adverse reactions commonly reported by COC users are:

    • Irregular uterine bleeding
    • Nausea
    • Breast tenderness
    • Headache

    Clinical Trial Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

    A phase 3 clinical trial evaluated the safety and efficacy of Layolis Fe for pregnancy prevention. The study was a multicenter, non-comparative, open-label study with a treatment duration of 12 months (thirteen 28-day cycles). A total of 1,677 women aged 18-46 were enrolled and took at least one dose of Layolis Fe.

    Adverse Reactions Leading to Study Discontinuation: 8.5% of the women discontinued from the clinical trial due to an adverse reaction. The most common adverse reactions leading to discontinuation were nausea (1.0%), weight increase (0.8%), acne (0.8%), metrorrhagia (0.7%), altered mood (0.4%), hypertension (0.4%), irritability (0.3%), migraine (0.3%), decreased libido (0.3%) and mood swings (0.3%).

    Common Adverse Reactions (≥ 2% of all treated subjects): nausea/vomiting (8.8%), headaches/migraine (7.5%), depression/mood complaints (4.1%), dysmenorrhea (3.9%), acne (3.2%), anxiety symptoms (2.4%), breast pain/tenderness (2.4%), and increased weight (2.3%).

    Serious Adverse Reactions: Hypertension, depression, cholecystitis, and deep vein thrombosis.

    Drug interactions

    No drug-drug interaction studies were conducted with Layolis Fe.

    Changes in Contraceptive Effectiveness Associated with Co-Administration of Other Products

    If a woman on hormonal contraceptives takes a drug or herbal product that induces enzymes, including CYP3A4, that metabolize contraceptive hormones, counsel her to use additional contraception or a different method of contraception. Drugs or herbal products that induce such enzymes may decrease the plasma concentrations of contraceptive hormones, and may decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include:

    • barbiturates
    • bosentan
    • carbamazepine
    • felbamate
    • griseofulvin
    • oxcarbazepine
    • phenytoin rifampin
    • St. John’s wort topiramate

    HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma levels of the estrogen and progestin have been noted in some cases of co-administration of HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.

    Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.

    Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.

    Increase in Plasma Levels of Ethinyl Estradiol Associated with Co-Administered Drugs

    Co-administration of atorvastatin and certain combination oral contraceptives containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels.

    Changes in Plasma Levels of Co-Administered Drugs

    COCs containing some synthetic estrogens (e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations.

    Use in specific populations

    Pregnancy

    There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non- genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy.

    The administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy. COCs should not be used during pregnancy to treat threatened or habitual abortion.

    Women who do not breastfeed may start COCs no earlier than four weeks postpartum.

    Nursing Mothers

    When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. Estrogen-containing OCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.

    Pediatric Use

    Safety and efficacy of Layolis Fe have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated.

    Geriatric Use

    Layolis Fe has not been studied in postmenopausal women and is not indicated in this population.

    Renal Impairment

    The pharmacokinetics of Layolis Fe have not been studied in subjects with renal impairment.

    Hepatic Impairment

    No studies have been conducted to evaluate the effect of hepatic disease on the disposition of Layolis Fe. However, steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal [see Contraindications (4), and Warnings and Precautions (5.3)].

    Body Mass Index

    The safety and efficacy of Layolis Fe in women with a BMI > 35 kg/m2 have not been evaluated.

    Overdosage

    There have been no reports of serious ill effects from overdose of oral contraceptives including ingestion by children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

    Description

    Layolis Fe provides an oral contraceptive regimen consisting of 24 tablets that contain the active ingredients specified below, followed by four non-hormonal placebo tablets:

    • 24 light green, round tablets each containing 0.8 mg norethindrone and 0.025 mg ethinyl estradiol
    • 4 brown, round tablets each containing 75 mg ferrous fumarate

    Each light green tablet also contains the following inactive ingredients: D&C Yellow No. 10 aluminum lake, FD and C Blue No. 1 aluminum lake, FD and C Yellow No. 6 aluminum lake, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, spearmint flavor, sucralose and vitamin E.

    Each brown, round tablet contains ferrous fumarate, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, spearmint flavor and sucralose. The ferrous fumarate chewable tablets do not serve any therapeutic purpose. Ferrous fumarate chewable tablets are not USP for dissolution and assay.

    The empirical formula of ethinyl estradiol is C20H24O2 and the chemical structure is:

    The chemical name of ethinyl estradiol is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol,(17α)-] The empirical formula of norethindrone is C20H26O2 and the chemical structure is:

    The chemical name of norethindrone is [17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one]

    Clinical pharmacology

    Mechanism of Action

    COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

    Pharmacodynamics

    No specific pharmacodynamic studies were conducted with Layolis Fe.

    Pharmacokinetics

    Absorption

    Norethindrone and ethinyl estradiol are absorbed with maximum plasma concentrations occurring within 2 hours after Layolis Fe administration (see Table 1). Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol.

    The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of Layolis Fe in 17 healthy female volunteers are provided in Table 1.

    Following multiple-dose administration of Layolis Fe, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 126% and 14%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 239% and 55% respectively, as compared to single-dose administration of Layolis Fe.

    Mean sex hormone binding globulin (SHBG) concentrations were increased by 170% from baseline (40.0 pg/mL; CV = 65%) to 108 pg/mL (CV = 45%) at steady-state.

    Table 1. Pharmacokinetic Parameter Values Following Single and Multiple Dose Administration of Layolis Fe

    Arithmetic mean parameters (%CV)
    Regimen Analyte Cmax tmax AUC0 - 24 h t½ *
    Day 1 (Single Dose) N = 17 NE 9,840 (36) 1.4 (49) 41,680 (47)
    EE 147 (27) 1.2 (25) 903 (18)
    NE 22,200 (30) 1.6 (76) 141,200 (32) 10.8
    EE 168 (25) 1.2 (35) 1,400 (32) 17.1

    EE = ethinyl estradiol; NE = norethindrone

    %CV = coefficient of variation; Cmax = maximum plasma concentration (pg/mL);

    tmax = time of the maximum measured plasma concentration (h);

    AUC0-24h = area under the plasma concentration versus time curve from time 0 to 24h (pg•h/mL);

    t½ = apparent elimination half life (h)

    *The harmonic mean for t½ is presented

    Food Effect

    Layolis Fe may be administered with or without food. A single-dose administration of Layolis Fe with food decreased the maximum concentration of norethindrone by 47% and increased the extent of absorption by 10-14% and decreased the maximum concentration of ethinyl estradiol by 39% but not the extent of absorption.

    Distribution

    Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (> 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis.

    Metabolism

    Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone is metabolically converted to ethinyl estradiol, such that exposure to ethinyl estradiol following administration of 1 mg of norethindrone acetate is equivalent to oral administration of 2.8 mcg ethinyl estradiol; therefore 0.8 mg norethindrone would be equivalent to the oral administration of 2.6 mcg ethinyl estradiol.

    Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation.

    Excretion

    Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Elimination half-lives of norethindrone and ethinyl estradiol following administration of 0.8 mg norethindrone / 0.025 mcg ethinyl estradiol tablets are approximately 11 hours and 17 hours, respectively.

    Specific Populations

    Pediatric Use: Safety and efficacy of Layolis Fe have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before menarche is not indicated.

    Geriatric Use: Layolis Fe has not been studied in postmenopausal women and is not indicated in this population.

    Renal Impairment: The pharmacokinetics of Layolis Fe have not been studied in subjects with renal impairment.

    Hepatic Impairment: The pharmacokinetics of Layolis Fe have not been studied in subjects with hepatic impairment. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal [see Contraindications (4), and Warnings and Precautions (5.3)].

    Body Mass Index: The efficacy of Layolis Fe in women with a BMI of > 35 kg/m2 has not been evaluated.

    Nonclinical toxicology

    Carcinogensis, Mutagenesis, Impairment of Fertility

    [See Warnings and Precautions (5.2, 5.3).]

    Clinical studies

    Oral Contraceptive Clinical Trial

    In a one-year (thirteen 28-day cycles) multicenter, open-label clinical trial, 1,677 women 18 to 46 years of age were studied to assess the safety and efficacy of Layolis Fe. The ethnic origin of the 1,570 treated subjects who were evaluable for efficacy was: Caucasian (72.0%), African-American (13.0%), Hispanic (11.2%) and Asian (1.8%). The weight range was 74 to 243 pounds with a mean weight of 148.8 pounds. Of treated women, 16.2% were lost to follow-up, 8.9% discontinued by withdrawing their consent and 8.5% discontinued due to an adverse event.

    The pregnancy rate (Pearl Index) in 1,251 women 18 to 35 years of age was 2.01 (95% confidence interval 1.21, 3.14) pregnancies per 100 women-years of treatment based on 19 pregnancies that occurred after onset of treatment and within 7 days after the last pill in 12,297 cycles of treatment during which no back-up contraception was used.

    How supplied/storage and handling

    How Supplied

    Layolis Fe is available in cartons of 3 blister cards (dispensers) (NDC 52544-064-31).

    Each blister card (28 tablets) contains in the following order:

    • 24 light green, round tablets (active) imprinted with “WC” on one side and “483” on the other and each containing 0.8 mg norethindrone and 0.025 mg ethinyl estradiol.
    • 4 brown, round tablets (non-hormonal placebo) imprinted with “WC” on one side and “624” on the other and each containing 75 mg ferrous fumarate.

    Storage Conditions

    Store at 20-25°C (68-77°F). [See USP controlled room temperature.]

    Keep out of reach of children.

    Patient counseling information

    See FDA-Approved Patient Labeling

    • Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs.
    • Counsel patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
    • Counsel patients on Warnings and Precautions associated with COCs.
    • Counsel patients to chew one tablet daily by mouth without water at the same time every day in the exact order noted on the blister. Instruct patients what to do in the event pills are missed. See What Should I Do if I Miss any Pills section in FDA-Approved Patient Labeling.
    • Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with Layolis Fe.
    • Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established.
    • Counsel any patient who starts COCs postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a light green tablet for 7 consecutive days.
    • Counsel patients that amenorrhea may occur. Pregnancy should be ruled out in the event of amenorrhea in two or more consecutive cycles.